Icon Legend

This session is not in your agenda.

This session is in your agenda. Click to remove it

Browse by Author

Home
Browse by Author

Browse by Author

Type here to filter the list

V
Valadez, Juan

Dr. Juan Antonio Valadez

P-009 - (Poster #9) Implementing a Brief, Culturally-Responsive Chronic Pain Management Curriculum
Location: Exhibit Hall (Level 4)

Juan Valadez

Favorite

Varrassi, Giustino

Fondazione Paolo Procacci Foundation

P-034 - (Poster #34) An Exploration of Painful Neuropathy in the Context of Long Covid: Mechanisms, Manifestations, and Management
Location: Exhibit Hall (Level 4)

Giustino Varrassi

Favorite

Vaughn, Ben

Rho, Inc.

P-044 - (Poster #44) Results of a Randomized, Placebo-Controlled, Phase 3 Trial of Cebranopadol for the Treatment of Acute Pain After Abdominoplasty
Location: Exhibit Hall (Level 4)

Ben Vaughn

Favorite

Vega, Charles

UC Irvine School of Medicine

P-031 - (Poster #31) Readability of Patient Pain Medication Management Instructions for Regimens Which Alternate Acetaminophen and Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
Location: Exhibit Hall (Level 4)

Charles Vega

Favorite

Virdi, Amaan

California University of Science and Medicine

P-061 - (Poster #61) The Role of PRP and MFAT in Enhancing Rotator Cuff Healing: Evidence from Recent Clinical Studies
Location: Exhibit Hall (Level 4)

Amaan Virdi

Favorite

Voburg, Suzanne

Uprise Health/Inflexxion

P-019 - (Poster #19) Opioid Abuse Deterrent Formulations: Evaluation of Nonmedical Use of Other Prescription Opioid Substances and Routes of Administration in Adults Evaluated for Substance Use Treatment with the Addiction Severity Index-Multimedia Version (ASI-MV®)
Location: Exhibit Hall (Level 4)

Suzanne Voburg

Favorite

P-020 - (Poster #20) Clinical Outcomes Translated to Healthcare Costs: Comparison of Buprenorphine Pain Medications with Full-agonist Extended-Release Opioids
Location: Exhibit Hall (Level 4)

Suzanne Voburg

Favorite

P-021 - (Poster #21) Route of Administration and Other Clinical Outcomes Among Exposures to Buprenorphine Pain Medications and Schedule II Opioids
Location: Exhibit Hall (Level 4)

Suzanne Voburg

Favorite

P-022 - (Poster #22) Urine Drug Test Results from Patients with Chronic Pain Receiving Partial Agonist Versus Full Agonist Opioid Therapy
Location: Exhibit Hall (Level 4)

Suzanne Voburg

Favorite

Vogt, Susanne

Viatris

P-038 - (Poster #38) Efficacy and safety of MR-107A-02 (novel meloxicam fast-acting formulation) for the treatment of acute moderate-to-severe pain following herniorrhaphy
Location: Exhibit Hall (Level 4)

Susanne Vogt

Favorite

P-039 - (Poster #39) Efficacy and safety of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy
Location: Exhibit Hall (Level 4)

Susanne Vogt

Favorite

P-040 - (Poster #40) Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy
Location: Exhibit Hall (Level 4)

Susanne Vogt

Favorite

SAP-08 - (Scientific Abstract Presentation) Opioid sparing effect of MR-107A-02 (novel fast-acting meloxicam formulation) for the treatment of acute moderate-to-severe pain following bunionectomy and herniorrhaphy
Location: Exhibit Hall (Level 4)

Susanne Vogt

Favorited

Vortsman, Eugene

Northwell Health

P-064 - (Poster #64) Stretching the Limits of Naloxone: Sufentanil and Naloxone-Resistant Contaminants in the Illicit Drug Supply
Location: Exhibit Hall (Level 4)

Eugene Vortsman

Favorite

SIS-03 - Real-World Use of Psychedelics: Intro to Synthetics
Location: Brera Ballroom (Level 3)

Eugene Vortsman

Favorite